CAR-T Cell Therapy Landscape: Kite Pharma Acquires Interius BioTherapeutics for $350 Million | DelveInsight's Perspective on Market Impact, Competitive Landscape and Pipeline Innovations

DelveInsight's latest analysis highlights the strategic significance of Gilead Sciences' subsidiary Kite Pharma's acquisition of Interius BioTherapeutics for $350 million, announced in August 2025. This landmark transaction reinforces Kite's leadership position in the CAR-T cell therapy market and expands its technological capabilities into next-generation allogeneic natural killer cell platforms, offering enhanced scalability and broader patient accessibility for cancer immunotherapy.
Key CAR-T Cell Therapy Market Highlights

*
Kite's acquisition of Interius strengthens its position in a CAR-T market expected to witness growth at a considerable CAGR through 2032.

*
The global CAR-T cell therapy pipeline encompasses 250+ companies and 500+ drugs in development, representing unprecedented innovation in cancer immunotherapy.

*
CAR-T Cell Therapy Companies: Gilead Sciences (NASDAQ: GILD), Novartis (NVS / NYSE: NVS), Bristol Myers Squibb (NYSE: BMY,), JW Therapeutics (HKEX: 2126), Autolus Therapeutics (NASDAQ: AUTL), Allogene Therapeutics (NASDAQ: ALLO), Cartesian Therapeutics (NASDAQ: RNAC), CARsgen Therapeutics (HKEX: 2171), Precision Biosciences (NASDAQ: DTIL), and others.

*
According to DelveInsight's analysis, the total CAR-T market size in the US across key indications totaled approximately $1.75 billion in 2023, with Non-Hodgkin's lymphoma accounting for approximately $1.2 billion, Multiple Myeloma ~$400 million, and Acute Lymphoblastic Leukemia ~$150 million.

Market Impact and CAR-T Patient Population

According to DelveInsight's CAR-T Cell Therapy Market Insight, Epidemiology and Market Forecast reports [https://www.delveinsight.com/report-store/chimeric-antigen-receptor-car-t-cell-therapy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr], the cell therapy landscape represents significant unmet medical needs across hematologic malignancies. In Non-Hodgkin's lymphoma, approximately 126K total eligible cases for CAR-T therapy existed in the 7MM in 2023, with DLBCL standing out as the most prevalent subtype. The US CAR-T market for NHL reached approximately $1.2 billion in 2023 and is projected to experience substantial growth through 2034.

The Multiple Myeloma CAR-T segment shows robust expansion, with the US market estimated at $400 million in 2022 and expected to demonstrate positive growth through 2032. In Acute Lymphoblastic Leukemia, the total incident cases in the US comprised ~7K cases in 2023, with the CAR-T market size reaching approximately $200 million across the 7MM.

The acquisition addresses critical manufacturing and scalability challenges inherent in autologous CAR-T therapies. Current approved therapies require complex patient-specific manufacturing processes, creating supply chain bottlenecks and limiting patient access. Interius's allogeneic NK cell platform offers potential "off-the-shelf" solutions that could dramatically improve treatment accessibility and reduce manufacturing timelines.

Download the CAR-T Cell Therapy Market report to understand which other factors are driving the therapeutic market @ CAR-T Cell Therapy Market Trends [https://www.delveinsight.com/sample-request/chimeric-antigen-receptor-car-t-cell-therapy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

Interius BioTherapeutics' Technology Platform

Interius BioTherapeutics brings a proprietary allogeneic natural killer (NK) cell engineering platform designed to overcome limitations of current autologous CAR-T approaches. The company's technology focuses on developing off-the-shelf NK cell therapies that can be administered without extensive patient-specific manufacturing requirements. Unlike traditional CAR-T cells that require weeks of manufacturing from each patient's T cells, Interius's platform enables rapid deployment of pre-manufactured cellular therapies.

"The acquisition of Interius represents a strategic evolution in our cell therapy capabilities," said Christi Shaw, CEO of Kite Pharma. "Their innovative NK cell platform complements our established CAR-T portfolio and positions us to deliver next-generation therapies that can reach more patients faster while potentially reducing manufacturing complexities and costs."

Strategic Validation and Market Positioning

The $350 million acquisition validates the growing importance of allogeneic cell therapies in addressing current market limitations. Kite's existing portfolio includes market-leading therapies YESCARTA (axicabtagene ciloleucel) and TECARTUS (brexucabtagene autoleucel), which have established strong market positions across multiple hematologic indications. YESCARTA captures significant patient share in DLBCL and follicular lymphoma, while TECARTUS remains the only CD19 CAR-T approved in third-line mantle cell lymphoma.

The acquisition strengthens Kite's competitive position against other major players including Novartis (KYMRIAH), Bristol Myers Squibb (BREYANZI, ABECMA), and emerging allogeneic developers such as Allogene Therapeutics, which is advancing cemacabtagene ansegedleucel (ALLO-501A) in Phase II trials.

CAR-T Competitive Landscape and Pipeline Innovation

The CAR-T competitive ecosystem includes 180+ companies developing 200+ pipeline candidates across various stages of development. Current approved CAR-T Cell therapies have demonstrated remarkable efficacy but face challenges including manufacturing complexity, high costs, and potential safety concerns such as cytokine release syndrome and neurotoxicity.

Key CAR-T therapies pipeline innovations include dual-targeting approaches, improved safety profiles, and expanded solid tumor applications. The CAR-T therapy companies are leveraging dual and triple targeting strategies, with players like Miltenyi Biomedicine developing CD19/20 bispecific CAR-T therapies and Novartis advancing CD79a/CD20 bispecific platforms. Approximately 90% of the current CAR-T market is dominated by aggressive B-cell NHL, with remaining segments including indolent B-cell NHL and plasma cell malignancies.

Explore more on how this deal is going to affect the CAR-T Cell Therapy competitive landscape @ CAR-T Cell Therapy Companies and Competitive Landscape [https://www.delveinsight.com/sample-request/chimeric-antigen-receptor-car-t-cell-therapy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

Emerging CAR-T Pipeline Therapy Developments

The acquisition occurs amid significant pipeline activity, with notable recent developments including Autolus Therapeutics' FDA approval of AUCATZYL (obecabtagene autoleucel) in January 2025 for relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Multiple companies are advancing next-generation approaches, including Cartesian Therapeutics' mRNA-engineered platform (Descartes-11), CARsgen Therapeutics' zevorcabtagene autoleucel, and various allogeneic platforms.

Furthermore, emerging CAR-T pipeline therapies are exploring novel targets beyond CD19 and BCMA, including GPRC5D, CD30, and BAFF-R signaling pathways. The pipeline demonstrates increasing focus on overcoming current limitations through improved manufacturing processes, enhanced safety profiles, and expanded target antigen coverage.

Discover more CAR-T Cell Therapy pipeline and the clinical development progress they are making @ CAR-T Cell Therapy Clinical Pipeline [https://www.delveinsight.com/sample-request/chimeric-antigen-receptor-car-t-cell-therapy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

Broader Strategic Implications

Beyond immediate portfolio expansion, Kite's acquisition of Interius positions the company for potential expansion into solid tumor applications and autoimmune diseases, where NK cell therapies may offer advantages over traditional T-cell approaches. The allogeneic platform could enable rapid clinical development across multiple indications without patient-specific manufacturing constraints.

Industry Expert Perspective

"The acquisition of Interius by Kite represents a strategic inflection point in cell therapy development," commented leading oncology analysts. "Allogeneic NK platforms address fundamental scalability challenges in current CAR-T manufacturing while potentially expanding therapeutic applications beyond hematologic malignancies. This transaction signals increasing industry recognition that next-generation cell therapies must overcome the logistical and economic barriers limiting current treatment accessibility."

Learn more about what other Industry experts are saying about this acquisition and how it will impact the CAR-T Cell Therapy treatment market @ Key Opinion Leaders on CAR-T Cell Therapy Market [https://www.delveinsight.com/sample-request/chimeric-antigen-receptor-car-t-cell-therapy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

Looking Forward

The Interius acquisition exemplifies the CAR-T industry's evolution toward more scalable, accessible therapeutic platforms. DelveInsight's analysts emphasize that while autologous CAR-T therapies have demonstrated transformative clinical efficacy, manufacturing scalability and cost considerations create opportunities for innovative approaches like allogeneic NK cell platforms. As the industry continues advancing toward broader patient accessibility and expanded therapeutic applications, strategic acquisitions like Kite's investment in Interius may define the next generation of cellular immunotherapy development.

Table of Contents

1. Key Insights

2. Executive Summary of CAR-T Cell Therapy

3. Competitive Intelligence Analysis for CAR-T Cell Therapy

4. CAR-T Cell Therapy Market Overview at a Glance

5. CAR-T Cell Therapy: Disease Background and Overview

6. CAR-T Cell Therapy Patient Journey

7. CAR-T Cell Therapy Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. CAR-T Cell Therapy Unmet Needs

10. Key Endpoints of CAR-T Cell Therapy Treatment

11. CAR-T Cell Therapy Marketed Products

12. CAR-T Cell Therapy Emerging Therapies

13. CAR-T Cell Therapy: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of CAR-T Cell Therapy

17. KOL Views

18. CAR-T Cell Therapy Market Drivers

19. CAR-T Cell Therapy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About DelveInsight Business Research

DelveInsight is a leading market research and consulting firm specializing in pharmaceutical and healthcare sectors. We provide comprehensive market intelligence, competitive analysis, and strategic insights to guide decision-making for life science companies globally.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cart-cell-therapy-landscape-kite-pharma-acquires-interius-biotherapeutics-for-350-million-delveinsights-perspective-on-market-impact-competitive-landscape-and-pipeline-innovations]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.